XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue     $ 50,641,000 $ 44,319,000   $ 106,544,000 $ 80,480,000  
Deferred Revenue     9,546,000     9,546,000   $ 12,740,000
Drug Product Revenue, Net [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue     729,000 14,272,000   25,216,000 $ 16,381,000  
Japan [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price, variable consideration from estimated future co-development billing           $ 0    
Japan [Member] | Drug Product Revenue, Net [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue       $ 14,400,000 $ 1,700,000      
Astellas Agreement [Member] | Japan [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront, non-contingent and time-based payments received   $ 172,600,000            
Additional consideration based on net sales description           the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     105,100,000     $ 105,100,000    
Changes in revenue from changes to estimated variable consideration           $ 0    
Astellas Agreement [Member] | Europe [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront, non-contingent and time-based payments received $ 745,000,000              
Additional consideration based on net sales description           low 20% range    
Aggregate consideration received excluding drug product revenue     $ 685,000,000     $ 685,000,000    
Percentage of joint development costs committed to fund 50.00%              
Changes in revenue from changes to estimated variable consideration           $ 0